Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
OpenAI Policy, Research, and Science Team Release Report Advocating for AI in Life Sciences; No AI-Discovered Drugs Through Phase III Clinical Trials Yet
OpenAI's policy, research, and science team released a report advocating for expanding AI applications in the life sciences. The report calls for opening access to more medical and scientific data, viewing advanced AI as a national-level research resource, and increasing investment in physical infrastructure such as computing power. The report states that AI can accelerate drug discovery, shorten clinical trial timelines by over 20%, and that GPT-5 Pro could find new uses for FDA-approved drugs for diseases with no effective therapies. However, the reality gap is significant; currently, only a very small number of AI-discovered drugs have entered clinical trials, and none have completed Phase III. A paper published in Nature Medicine in mid-2025 shows that AI-discovered drugs in Phase II trials...